IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about General Updates

Regulatory product approvalBusiness Updates View source PDF Explain this filing

IOLCP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.2%Reaction day

₹73.55

prior close

₹72.90

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-2.7%+0.4% vs market

Pharmaceuticals peers, median of 158sector-1.2%-1.1% vs sector

On the reaction day the stock moved 0.4 pts more than Nifty Microcap 250 and 1.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.2

10m

-2.6

15m

-2.1

30m

-2.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.2-2.7+0.4-1.2-1.1

Next day

-1.3-0.3-0.9+0.6-1.9

-2.8-0.5-2.4+0.0-2.8

-3.6-0.8-2.9-0.2-3.4

-6.1-3.6-2.4-2.5-3.5

-6.9-4.2-2.6-3.6-3.3

+0.7-0.7+1.4-2.2+2.9

15d

+5.1-3.4+8.5-4.9+10.0

+9.8+2.6+7.1+1.3+8.5

+47.7+15.6+32.1+9.9+37.8

+80.8+16.6+64.2+11.2+69.6

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 158Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

IOL Chemicals and Pharmaceuticals has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Health Care (EDQM) for its API product Metformin Hydrochloride (Process-II), granted on 5th March 2026. This is an additional CEP — the company already holds a valid CEP for Metformin Hydrochloride under a different process. Metformin is a widely used antidiabetic medication for managing high blood sugar in diabetes patients. The CEP is a regulatory clearance required to market an API in European markets.

Likely market impact

This strengthens IOL's regulatory standing in Europe for a high-volume diabetes API and gives European customers a second approved process to source from, which could support export volumes and pricing power. Positive for the stock on regulatory progress, though no immediate revenue numbers are disclosed.